Xavier Delavenne

2.3k total citations
105 papers, 1.6k citations indexed

About

Xavier Delavenne is a scholar working on Cardiology and Cardiovascular Medicine, Hematology and Surgery. According to data from OpenAlex, Xavier Delavenne has authored 105 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Cardiology and Cardiovascular Medicine, 21 papers in Hematology and 17 papers in Surgery. Recurrent topics in Xavier Delavenne's work include Atrial Fibrillation Management and Outcomes (25 papers), Venous Thromboembolism Diagnosis and Management (17 papers) and Hemophilia Treatment and Research (12 papers). Xavier Delavenne is often cited by papers focused on Atrial Fibrillation Management and Outcomes (25 papers), Venous Thromboembolism Diagnosis and Management (17 papers) and Hemophilia Treatment and Research (12 papers). Xavier Delavenne collaborates with scholars based in France, United States and United Kingdom. Xavier Delavenne's co-authors include Patrick Mismetti, Thierry Basset, Silvy Laporte, Sophie Hodin, Édouard Ollier, Laurent Bertoletti, Nathalie Perek, Paul Zufferey, Patrick Mismetti and Virginie Siguret and has published in prestigious journals such as Blood, Journal of the American College of Cardiology and Clinical Infectious Diseases.

In The Last Decade

Xavier Delavenne

97 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xavier Delavenne France 23 724 386 232 207 154 105 1.6k
Atef Halabi Germany 25 805 1.1× 335 0.9× 306 1.3× 91 0.4× 315 2.0× 79 2.2k
Wonkyung Byon United States 17 1.1k 1.6× 674 1.7× 132 0.6× 60 0.3× 60 0.4× 29 1.7k
Rebecca A. Boyd United States 21 1.4k 1.9× 800 2.1× 265 1.1× 64 0.3× 88 0.6× 34 2.4k
C. Steven Ernest United States 22 1.4k 1.9× 311 0.8× 662 2.9× 91 0.4× 113 0.7× 41 2.1k
Éric Pautas France 20 522 0.7× 440 1.1× 187 0.8× 114 0.6× 48 0.3× 80 1.4k
Diane K. Jorkasky United States 27 425 0.6× 116 0.3× 353 1.5× 96 0.5× 180 1.2× 68 1.7k
Georg Wensing Germany 22 1.4k 2.0× 814 2.1× 279 1.2× 237 1.1× 463 3.0× 73 2.6k
Caroline Samer Switzerland 28 406 0.6× 140 0.4× 199 0.9× 104 0.5× 97 0.6× 107 2.5k
Simon de Denus Canada 24 1.1k 1.5× 147 0.4× 383 1.7× 58 0.3× 138 0.9× 96 1.9k
Antoinette Mangione United States 17 526 0.7× 328 0.8× 146 0.6× 607 2.9× 152 1.0× 36 1.9k

Countries citing papers authored by Xavier Delavenne

Since Specialization
Citations

This map shows the geographic impact of Xavier Delavenne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xavier Delavenne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xavier Delavenne more than expected).

Fields of papers citing papers by Xavier Delavenne

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xavier Delavenne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xavier Delavenne. The network helps show where Xavier Delavenne may publish in the future.

Co-authorship network of co-authors of Xavier Delavenne

This figure shows the co-authorship network connecting the top 25 collaborators of Xavier Delavenne. A scholar is included among the top collaborators of Xavier Delavenne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xavier Delavenne. Xavier Delavenne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Féliu, Catherine, et al.. (2025). Investigating 3-CMC metabolism: Insights from liver microsomes and postmortem biological matrix. Forensic Science International. 367. 112364–112364.
2.
Hodin, Sophie, et al.. (2025). Long‐term evaluation of rheumatoid arthritis activity with erythrocyte methotrexate‐polyglutamate 3. Fundamental and Clinical Pharmacology. 39(1). e13050–e13050. 2 indexed citations
3.
Guillet, Benoît, Roseline d’Oiron, Marc Trossaërt, et al.. (2025). F8 gene variants influence the response to desmopressin in hemophilia A carriers. Blood. 146(16). 1991–2004.
4.
Bertoletti, Laurent, Athénaïs Boucly, Ségolène Turquier, et al.. (2025). Association Between Anticoagulant Therapy and Survival in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology. 86(13). 982–995.
5.
6.
Poénou, Géraldine, et al.. (2024). Latest advances in the reversal strategies for direct oral anticoagulants. Fundamental and Clinical Pharmacology. 38(4). 674–684. 2 indexed citations
7.
Poénou, Géraldine, et al.. (2024). Tailoring oral anticoagulant treatment in the era of multi-drug therapies for PAH and CTEPH. Blood Reviews. 68. 101240–101240. 1 indexed citations
8.
Guillet, Benoît, B. Wibaut, Annie Harroche, et al.. (2023). A French Real-World Evidence Study Evaluating the Efficacy, Safety, and Pharmacokinetic Parameters of rVIII-SingleChain in Patients with Hemophilia A Receiving Prophylaxis. Thrombosis and Haemostasis. 123(5). 490–500. 2 indexed citations
9.
10.
Leclerc, Lara, Nathalie Prévôt, Sophie Hodin, et al.. (2023). Acoustic Aerosol Delivery: Assessing of Various Nasal Delivery Techniques and Medical Devices on Intrasinus Drug Deposition. Pharmaceuticals. 16(2). 135–135. 5 indexed citations
11.
Tardy, Brigitte, Thierry Lambert, Marc Trossaërt, et al.. (2022). Revised terminal half‐life of nonacog alfa as derived from extended sampling data: A real‐world study involving 64 haemophilia B patients on nonacog alfa regular prophylaxis. Haemophilia. 28(4). 542–547. 4 indexed citations
12.
Hodin, Sophie, R. Philippot, Serge Molliex, et al.. (2021). Population pharmacokinetic model of cefazolin in total hip arthroplasty. Scientific Reports. 11(1). 19763–19763. 8 indexed citations
13.
Zufferey, Paul, et al.. (2020). Exposure–Response Relationship of Tranexamic Acid in Cardiac Surgery. Anesthesiology. 134(2). 165–178. 40 indexed citations
14.
Hé, Zhiguo, Sophie Hodin, Samuel Constant, et al.. (2019). Pharmacological characterization of the 3D MucilAir™ nasal model. European Journal of Pharmaceutics and Biopharmaceutics. 139. 186–196. 44 indexed citations
15.
Jourdi, Georges, Maxime Delrue, Alain Stépanian, et al.. (2019). Potential usefulness of activated charcoal (DOAC remove®) for dRVVT testing in patients receiving Direct Oral AntiCoagulants. Thrombosis Research. 184. 86–91. 33 indexed citations
16.
Siguret, Virginie, Xavier Delavenne, Emmanuel Curis, et al.. (2019). Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variability. Journal of Thrombosis and Haemostasis. 17(10). 1670–1682. 19 indexed citations
17.
Zufferey, Paul, et al.. (2017). Intravenous Tranexamic Acid Bolus plus Infusion Is Not More Effective than a Single Bolus in Primary Hip Arthroplasty. Anesthesiology. 127(3). 413–422. 32 indexed citations
18.
Pons, Bertrand, Xavier Delavenne, Marie‐Noëlle Beyens, et al.. (2012). Intoxications graves au méprobamate : description d’une série de 146 cas dans le département de la Loire. Therapies. 67(2). 183–189. 4 indexed citations
19.
Gouin‐Thibault, Isabelle, Patrick Mismetti, Claire Flaujac, et al.. (2011). Nouveaux anticoagulants par voie orale : quelle place pour les analyses de biologie médicale ?. Sang thrombose vaisseaux. 23(1). 8–17. 5 indexed citations
20.
Delavenne, Xavier, et al.. (2010). UPLC MS/MS method for quantification of mycophenolic acid and metabolites in human plasma: Application to pharmacokinetic study. Clinica Chimica Acta. 412(1-2). 59–65. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Atef Halabi Breakdown of academic impact, for papers by Wonkyung Byon Breakdown of academic impact, for papers by Rebecca A. Boyd Breakdown of academic impact, for papers by C. Steven Ernest Breakdown of academic impact, for papers by Éric Pautas Breakdown of academic impact, for papers by Diane K. Jorkasky Breakdown of academic impact, for papers by Georg Wensing Breakdown of academic impact, for papers by Caroline Samer Breakdown of academic impact, for papers by Simon de Denus Breakdown of academic impact, for papers by Antoinette Mangione
Rankless by CCL
2026